

**COMPOSITIONS COMPRISING GENOME SEGMENTS  
AND METHODS OF USING THE SAME**

**CROSS REFERENCE TO RELATED APPLICATIONS**

This application claims priority to U.S. Provisional Application No.  
5 60/174,155 filed January 3, 2000, which is incorporated herein by reference.

**FIELD OF THE INVENTION**

The present invention relates to compositions and methods of treating  
individuals with diseases and disorders associated with genetic mutations. According to  
the present invention, DNA is administered to individuals who take it up and replace DNA  
10 with mutated sequences with DNA with non-mutated sequences or substitute existing set  
of alleles to a different one. The present invention also relates to compositions and  
methods for preventing and treating infections, allergies, transplant rejections and  
infertility.

**BACKGROUND OF THE INVENTION**

15 Every cell of an organism contains genomic DNA that keeps encoded  
information about all proteins of all cells of the organism and eventually about the whole  
organism and its development. Initially this genomic DNA is identical in all cells of an  
organism. But as the organism grows genomic DNA of every cell becomes subjected to

mutational pressure due to environmental factors and mistakes of cellular replication and repair machinery. The known cellular DNA repair mechanisms replace damaged or incorrect DNA bases and rejoin ends of DNA after single-strand and double-strand breaks immediately after mutational events. They can also employ the second DNA chain as a

5 template. When the damage is rather long and affects both DNA chains its repair becomes problematic and the damage results in mutation. The double-strand break repair mechanism can itself be a source of mutations (Pfeifer, P., The mutagenic potential of DNA double-strand break repair. 1998, 96-97, 119-129). As mutations are accumulated in the cellular genome they can cause malfunction of some cells or cancerous transformation.

10 Environmental mutagenic factors and errors of cellular replication and repair are sources of somatic cell mutations. It has been suggested that gradual accumulation of mutations in cells can cause multi-step cancer transformation. Somatic mutations are considered to be the main cause of aging. Mutations may also induce development of some hereditary associated diseases such as cardio-vascular diseases, high

15 blood pressure, rheumatoid arthritis, and diabetes.

The genetic, multi-mutational nature of cellular cancer transformation and cancer itself suggests that methods of cancer therapy should be directed to the cause of the disease and particularly targeted to the treatment of mutations. Methods for fixing definite point mutations in cells have been suggested (U.S Patent No. 5,795,972 issued to Kmiec

20 on August 18, 1998, which is incorporated herein by reference) but according to the method, mutations must be precisely identified before each treatment. Because not a single mutation has been 100% proven to cause a cancer, the development of these methods requires additional fine and time-consuming research. There is a need for methods which can be applied based upon the current knowledge underlying the causes of cancer.

25 Applying DNA fragments locally has been suggested for treatment of precancerous conditions in skin of patients and for tanning stimulation (U.S. Patent No. 5,955,059 issued to Gilchrest, et al., on September 21, 1999; and U.S. Patent No. 5,470,577 issued to Gilchrest, et al., November 28, 1995, both of which are incorporated herein by reference). No sequences or sources of DNA are specified. Rather, the patent

30 suggests that 'any appropriate sources' DNA natural or synthetic, for example, salmon DNA with the length from 200 to mononucleotides and nucleosides including dimers, the

09753662.010301

most potent agents in their tests can be used.

Another method to activate DNA repair in cells is offered including delivery of enzymes participating in DNA repair into skin cells (U.S. Patent No. 5,352,458 issued to Yarosh, October 4, 1994; and U.S. Patent No. 5,302,389 issued to Kripke, et. al., April 12, 1994, both of which are incorporated herein by reference). However the latter methods do not suggest fixing of already established or inherited mutations.

There remains a need for methods of correcting genetic mutations. There remains a need for treating individuals who have diseases and disorders associated with genetic mutations. There remains a need to replace undesirable alleles with desirable alleles. There is a further need for methods for inducing tolerance to prevent transplant rejection. There is a further need for methods for inducing tolerance to treat and prevent allergies. There is a need for methods for increasing fertility.

#### SUMMARY OF THE INVENTION

The present invention arises from the surprising discovery that when an entire genome is administered to an individual in the form of a plurality of polynucleotide molecules that are fragments of genomic DNA, the polynucleotide molecules will circulate, be taken up by cells and translocate to the nucleus of the cells where they will recombine by homologous recombination with the genomic DNA of the cell. Accordingly, genetic defects can be corrected by administering an entire genome to an individual in the form of polynucleotide molecules that are fragments of genomic DNA that are free of the genetic defect. Individuals with diseases and disorders associated with genetic mutations can be effectively treated by the present invention.

Human genomic DNA fragments are used for treating cancer and other diseases caused by mutations. Nucleic acid molecules derived from "healthy" donor DNA is administered to the patient. The nucleic acid molecules correct mutational changes in cells via homologous recombination with mutated genomic sequences. This mechanism modifies allelic genes and in this way an antigenic structure of organism in accordance with composition of administered nucleic acid molecules. The present invention is useful for induction of immunological tolerance at transplantation or pregnancy.

The present invention relates to methods of treating individuals who have

09753692.010301

diseases or disorders associated with a genetic mutation or undesirable allele in genomic DNA and to methods of preventing individuals from developing diseases or disorders associated with a genetic mutation or undesirable allele in genomic DNA. According to the invention a segment of genomic DNA that has a mutated sequence or undesirable allele

5 is replaced with a corresponding segment of DNA that has a non-mutated sequence or desirable allele. The methods comprise the step of administering to the individual an effective amount of a plurality of polynucleotide molecules that are free of vector sequences. The plurality of polynucleotide molecules collectively comprises an essentially complete genome in polynucleotide molecules having about 100-3000 nucleotides, and

10 includes a polynucleotide molecule which comprises a non-mutated sequence or desirable allele corresponding to the genetic mutation or undesirable allele in the genomic DNA of the cell in the individual. At least some of the plurality of polynucleotide molecules including the polynucleotide molecule which comprises the non-mutated sequence or desirable allele are taken up by the cell of the individual which has the genetic mutation or

15 undesirable allele in genomic DNA, transported to the nucleus of the cell, and recombine with the genomic DNA of the cell by homologous recombination. The mutated sequence or undesirable allele of genomic DNA of the cell is replaced by the non-mutated sequence or desirable allele to correct the genetic mutation in the genomic DNA or incorporate the desirable allele into the genomic DNA.

20 The present invention relates to methods of inducing tolerance and preventing transplant rejection in an individual comprising the steps of administering to the individual an effective amount of a plurality of polynucleotide molecules that are free of vector sequences. The plurality of polynucleotide molecules collectively comprises an essentially complete genome of the donor in polynucleotide molecules having about 100-

25 3000 nucleotides. At least some of the plurality of polynucleotide molecules are taken up by the cell of the individual, are transported to the nucleus of the cell, and recombine with the genomic DNA of the cell by homologous recombination. The genomic DNA of the individual is replaced by genomic DNA of the donor and tolerance is induced and transplant rejection is reduced in the individual.

30 The present invention relates to methods of inducing tolerance and treating allergies in an individual comprising the steps of administering to the individual an

09/53882-040301

effective amount of a plurality of polynucleotide molecules that are free of vector sequences. The plurality of polynucleotide molecules collectively comprises an essentially complete genome of the donor in polynucleotide molecules having about 100-3000 nucleotides. At least some of the plurality of polynucleotide molecules are taken up by the  
5 cell of the individual, are transported to the nucleus of the cell, and recombine with the genomic DNA of the cell by homologous recombination. The genomic DNA of the individual is replaced by genomic DNA of the donor and tolerance is induced and allergies are reduced in the individual.

The present invention further relates to methods of increasing fertility in a  
10 woman. The methods comprise the step of administering to the woman an effective amount of a plurality of polynucleotide molecules that are free of vector sequences. The plurality of polynucleotide molecules collectively comprises an essentially complete genome of a prospective father in polynucleotide molecules having about 100-3000 nucleotides. At least some of the plurality of polynucleotide molecules are taken up by  
15 cells of the woman, transported to the nucleus of the cell, and recombine with the genomic DNA of the cell by homologous recombination. Genomic DNA of the woman is replaced by genomic DNA of the prospective father and fertility is improved in the woman.

The present invention relates to methods of preventing or reducing graft versus host disease in a recipient comprising the steps of administering to the donor an  
20 effective amount of a plurality of polynucleotide molecules that are free of vector sequences. The plurality of polynucleotide molecules collectively comprises an essentially complete genome of the recipient in polynucleotide molecules having about 100-3000 nucleotides. At least some of the plurality of polynucleotide molecules are taken up by the cells of the recipient, transported to the nucleus of the cell, and recombine with the  
25 genomic DNA of the cell by homologous recombination. The genomic DNA of the donor is replaced by genomic DNA of the recipient. Following transplantation/grafting, the level of graft versus host disease is reduced or prevented.

The present invention relates to methods of introducing one or more desirable alleles into livestock which contains undesirable alleles comprising the steps of  
30 administering to the livestock an effective amount of a plurality of polynucleotide molecules that are free of vector sequences. The plurality of polynucleotide molecules

09753802.010304

collectively comprises an essentially complete genome of the livestock species in polynucleotide molecules having about 100-3000 nucleotides including the desirable alleles. At least some of the plurality of polynucleotide molecules are taken up by the cells animal, transported to the nucleus of the cell, and recombine with the genomic DNA of the  
5 cell by homologous recombination. The undesirable alleles in the genomic DNA of the animal is replaced by the desirable alleles.

The present invention relates to an apparatus for doing large scale PCR preparations. The apparatus comprises a reaction tube that has an inner diameter of 3 mm or more, at least one pump for continuously supplying of reagents to the reaction tube, four  
10 temperature chambers and a collection vessel. The reagents are combined and enter the reaction tube by action of the pump. The reaction tube comprises a series of reaction tube lengths which alternately pass through each of the four temperature chambers to produce a cycle segment, such that a length of the reaction tube passes through the first temperature chamber, a length of the reaction tube passes through the second temperature chamber, a  
15 length of the reaction tube passes through the third first temperature chamber, a length of the reaction tube passes through the fourth temperature chamber to produce a cycle segment. The reaction tube comprises at least twenty consecutive cycle segments and is connected to the collection vessel following the last cycle segment.

The present invention relates to pharmaceutical compositions that  
20 comprises, in a pharmaceutically acceptable carrier, a plurality of polynucleotide molecules which collectively comprise an essentially complete genome in polynucleotide molecules having about 100-3000 nucleotides.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A shows changes in specific protein expression in human cancer  
25 cells induced by preparations of human DNA. Three assays were run on each of three cancer cell types (human breast cancer cells BT474, ovarian carcinoma cells OVCAR5 and promyelocytic leukemia cells HL60) and expression was tested of proteins associated with cancer, erbB2 for BT474 and OVCAR5 cells, c-myc for HL60 cells and cyclin D1 for all three cell types. Figure 1A contains six autoradiograms; in each lane C designates the  
30 control human breast cancer cells BT474, ovarian carcinoma cells OVCAR5 and

09753892.010301

promyelocytic leukemia cells HL60; each lane D designates the same cells treated for 2 weeks with DNA preparations (2 $\mu$ g/well); each lane Ch designates the same cells treated for 2 weeks with chromatin preparations (2 $\mu$ g of DNA per well). Equal protein amounts of cell lysates were electrophoresed in SDS-PAAG and transferred to nitrocellulose

5 membranes by Western blotting procedure. The membranes were incubated with specific antibodies to proteins Erb-B2, C-Myc and Cyclin D1, washed in buffer and incubated with secondary antibodies conjugated with HRP according to protocols of Santa Cruz Biotech. Co. The membranes were then washed and developed with Luminol reagent and exposed to X-ray film. Fig.1A shows specific protein expression, X-ray films

10 Figure 1B is a bar graph depicting protein quantitation data corresponding to the data in Figure 1A.

Figure 2 shows the survival of A/He mouse strain specific tumor allograft in immunologically incompatible CBA mice injected with A/He strain DNA preparations. Two types of preparations were used: 1) A/He purified total chromatin digested by  
15 micrococcal nuclease to oligonucleosome size fragments (200-3000 bp DNA) (diamond cross, XXXX). 2) A/He isolated genomic DNA mildly sonicated to obtain 200-3000 bp size fragments (///). The following schemes of DNA treatments were applied to 4 groups of the recipient CBA mice: 1 - injection of physiological salt solution (control group); 2 - single i.p. injection of either DNA or chromatin preparation (40  $\mu$ g of DNA per injection  
20 in the form DNA and chromatin) on the second day after birth; 3 - a series of 4 injections of either DNA or chromatin preparation (40  $\mu$ g of DNA per injection in the form of DNA or chromatin) every 5 days starting with the second day after birth; 4 - a series of 3 injections of chromatin (40  $\mu$ g of DNA per injection) every 5 days starting from the 6<sup>th</sup> day after birth. Hepatoma A tumors were inoculated into treated and control mice 25 days  
25 after single preparation injection or one week after last injection at multi-injectional therapy. In two weeks approximately 30% of mice that received DNA preparations developed cancer at the spot of inoculation.

Figure 3 shows data from random human genomic DNA amplification in PCR reaction. A random primer PCR procedure was used according to Telenius et al.  
30 (1992) with modifications. Telenius's 18-mer partially degenerate oligonucleotide primer DOP 6-MW (5'CCGACTCGAGNNNNNNATGTGG SEQ ID NO:1) was used for random

09753692.010301

DNA amplification in Idaho Technology rapid thermal cycler. Reaction mixture 50  $\mu$ l contained 1 ng of human DNA, PCR buffer with 0.2 mM  $MgCl_2$ , 0.2 mM NTP, 2  $\mu$ M DOP 6-MW and 40 U/ml Taq polymerase. After denaturing of the mixture at 95°C for 5 min it was incubated 10 sec at 94°C, 10 sec at 53°C and 30 sec at 72°C for different  
5 number of times with final exposure 10 min at 72°C. Samples were resolved in 1% agarose gel in TBE buffer and bands were visualized in UV light after ethidium bromide staining. Lanes are corresponding to: 1 to 15 thermal cycles, 2 – 25 cycles, 3 – 35 cycles, 4 – 45 cycles and 5 – molecular weight standards. From the picture one can see that although 15 cycles give low yield, other variants give nearly the same yields of DNA product. Thus  
10 using 1 ng of the DNA in a 50  $\mu$ l reaction mixture we can get up to 10  $\mu$ g DNA fragments 200-3000 bp in length.

Figure 4 is a schematic drawing of the apparatus for large scale amplification of genomic DNA as described in Example 4.

#### DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION

- 15 The mechanisms of entering of oligo- and polynucleotides into living organisms, their distribution between tissues and organs, and particularly the methods of their penetration into living cells have been studied. Specific cell surface proteins have been found to bind to nucleic acid molecules and deliver them into the acidic vesicular endosomal compartment inside cells and further on into cell nuclei. Oligonucleotides and  
20 polynucleotides have been shown to enter cells via a saturable, partially reversible receptor-mediated endocytosis mechanism. It has been observed that nucleic acids can enter a mammalian organism via gastrointestinal and other mucosas or even through the skin. Having been injected intravenously or intraperitoneally they were delivered systemically by circulation to all cells of the organism.
- 25 An even more exciting discovery about these receptors has now been made. The same proteins that bind oligonucleotides on the cell surface are responsible for their delivery into the cell nucleus. Thus nuclear oligonucleotide delivery was found to be a multi-step process employing the cell surface receptors and resulting in reversible redistribution of the receptors in the cell to mostly nuclear localization and the process was  
30 activated by extracellular oligonucleotides.



Nucleic acid fragments are normally present in plasma and tissue fluids. They are constantly produced in organisms as a result of cellular death via apoptosis (programmed cell death) and necrosis of cells and consist mainly of the fragmented genomic DNA complexed with nuclear proteins. This fragmented genomic DNA can be  
5 taken up by cells of the body, then transported to cellular nuclei and finally can be employed as an external DNA standard for repair of mutations in cells via homologous recombination of the delivered DNA fragments with cellular genomic DNA.

Although the present invention is expressly not intended to be limited by any theory, the data suggest a possible reason related to the discoveries underlying the  
10 present invention. The data suggest that there exists a global genomic DNA repair system which uses extracellular DNA fragments from blood circulation or surrounding tissue fluids as a standard for genomic DNA correction in cells by means of homologous recombination, and which works continuously in every cell of the human body although it is unclear yet to what extent this mechanism resists mutational changes of the cellular  
15 genome. The global genomic repair system appears to have three main parts or steps of action: i) generation of extracellular fragmented genomic DNA in an organism, ii) cellular uptake and nuclear delivery of the nucleic acid fragments, and iii) homologous recombination of the fragments with genomic DNA. The system stands guard over invariability of the genome and eliminates mutations in every cell of an organism.

20 Although extracellular nucleic acids can have some misspelled sequences from the death of rare mutated but unrepaired cells, the percentage of such sequences compared to the 'correct' DNA is usually extremely low. However if mutated cells are numerous, they themselves may become a source of mutated plasma DNA (especially if these cells undergo increased apoptosis or necrosis). This can result in multiple mutations  
25 of cells in the body. The quantity of mutations will depend on the percentage of mutant DNA in the plasma DNA reservoir. The death of new mutated cells will produce mutated DNA that will increase the proportion of mutated DNA in plasma DNA. This in turn will increase the number of mutated cells via recombination with cellular DNA. An increase in mutated sequences in plasma DNA will be followed by an increase in the proportion of  
30 mutated cells in the organism and may further lead to multiple mutations in cells of the body. Depending on how a mutation affects certain properties of cells (e.g. rate of

09753692-010301

0753892-010301  
multiplication or tendency towards apoptosis or necrosis) the percentage of the mutated DNA in plasma DNA will either increase or decrease. Since many different mutations can be displayed in cellular populations of an organism, the mutated sequences will be presented in extracellular DNA of circulation and tissue fluids in corresponding

- 5 proportions with corrections to the relative rates of cell death in mutated cells. Because such DNA fragments will simultaneously perform repair of mutations in some cells and induce mutations in others, all cells of the organism will be in a state of mobile mutational equilibrium. This equilibrium can be shifted by a variety of factors, such as the possibility for free DNA of the cellular surroundings to play a more important role in the
- 10 recombination than that of plasma DNA. These processes can change frequencies of mutations in the body and cellular communities and cause gradual drift of the plasma DNA standard. Therefore in light of this theory, cancer and aging may not be diseases of cells or cellular clones, but those of the genome of the organism. If such a global DNA proofreading mechanism exists, any damage or malfunction of its components will result
- 15 in genetic instability of cells in the organism, accelerating carcinogenesis, premature aging or other disorders.

- The theory considered above suggests, that horizontal transfer of genetic material between cells in the body is usually normal state of cellular community. This concerns not only proper inherited genomic DNA but any DNA that happen to be
- 20 introduced into the body. This DNA will certainly recombine with genomic DNA at sites of homology, and the frequencies (and number of sequences or genes ready to recombine) of recombination will correlate primarily with extent of the relation: high and very high frequencies between DNAs of the same species, lower between remote species and rare between far remote species. Herewith frequencies of recombination for separate
- 25 homologous genes will be the same regardless of hereditary relations.

### Definitions

- As used herein, the term "individual" refers to the vertebrate targeted for use of the present invention. Examples of "individuals" contemplated by the present invention include but are not limited to humans, higher order primates, canines, felines,
- 30 bovines, equines, ovines, porcines, avians, and other mammals.

As used herein, the term "diseases and disorders associated with genetic

mutations" refers to: cancer; heart and blood vessel diseases; peripheral blood vessel diseases; autoimmune diseases; diabetic conditions; neurodegenerative conditions; gastroenterological and hepatological diseases; mutagenic pathogen disorders; classic hereditary diseases; disorders due to exposure to mutagenic stimuli; other multifactorial diseases; hereditary predisposition to one of the above-mentioned diseases; and aging

As used herein, the term "administration" refers to the delivery of polynucleotide molecules to the individual. The term includes, but is not limited to delivery routes including intramuscularly, intravenously, intranasally, intraperitoneally, intradermally, intrathecally, intraventricularly, subcutaneously, transdermally or topically or by lavage. Modes of administration contemplated by this invention include but are not limited to the use of a syringe, intravenous line, transdermal patch, or needleless injector.

As used herein, the term "segment" refers to a portion of genomic DNA with or without mutations.

As used herein, the term "allele" used in the context of an undesirable allele being replaced with a desired allele refers to the entire gene or a portion of the gene such that following recombination with a portion of the gene, the undesirable allele is replaced with the desirable allele. Accordingly, the polynucleotide molecules used to replace an undesirable allele need not comprise the entire gene but enough of the gene to effectively convert the undesirable allele into a more desirable form.

As used herein, the phrase "plurality of polynucleotide molecules that are free of vector sequences" refers to a composition that comprises multiple different nucleic acid molecules which are fragments or copies of fragments of genomic DNA. The nucleic acid molecules are preferably DNA. The nucleic acid molecules do not include sequences other than genomic sequences. A "plurality of polynucleotide molecules that are free of vector sequences" does not contain any vector sequences such as viral or cell sequences from a vector host.

As used herein, the phrase "each polynucleotide molecule has 100-3000 nucleotides" refers to the number of nucleotide bases on a single strand of a nucleic acid molecule. A double stranded nucleic acid molecule such as a DNA would contain 200-6000 nucleotides as 100-3000 base pairs.

As used herein, the phrase "plurality of polynucleotide molecules

09753892.010301

collectively comprises an essentially complete genome" refers to the composition, which if assembled would equal a complete genome. The plurality of polynucleotide molecules are a plurality of fragments of genomic DNA or a plurality of copies of fragments of genomic DNA. For example, in some embodiments, a complete genome of genomic DNA is

- 5 isolated from an individual, such as isolated chromosomal DNA, fragmented into a plurality of fragments by mechanical sheering and/or sonication and/or partial enzymatic digestion and/or restriction endonuclease digestion. Such a fragmented chromosomal isolate collectively comprises an essentially complete genome. Likewise, copies of an entire genome can be made and amplified by polymerase chain reaction using random
- 10 primers and whole genome chromosomal DNA as a template. The plurality of polynucleotide molecules generated by such amplification techniques "collectively comprises an essentially complete genome" in that essentially the entire genomic DNA is copied and found within any one or more of the several randomly produced amplification products which are copies of fragments of genomic DNA.

- 15 As used herein, the phrase "plurality of polynucleotide molecules includes a polynucleotide molecule which comprises a non-mutated sequence corresponding to the genetic mutation in the genomic DNA of the cell in the individual" is meant to refer to the use of genomic DNA chromosomal starting material from sources believed to be free of the mutated sequence which means that the mutated sequence may be present in such low
- 20 percentage that in a healthy person it does not induce any pathology. For example, autologous starting material derived from a patient at an early age or prior to exposure to mutagenic stimuli may be used. Similarly, starting material derived from a donor who is not believed to be a carrier or otherwise possess the genetic mutation associated with a patient or at least is not suffering from the disease. In some cases, the exact nature of
- 25 genetic mutation associated with a patient may be unknown and the starting material derived from a donor who is not patient and therefore believed to be free of the genetic mutation. In some cases, the exact nature of genetic mutation associated with a patient may be known and associated with specific cells, such as tumor cells. The starting material may be derived from non-tumor tissue of the patient and therefore believed to be
- 30 free of the genetic mutation but this may not be the best idea because even non-tumor tissues of the patient may have the predisposition to develop into a tumor.

09753692-010301

As used herein, the term "treatment" is meant to refer to stabilization, reduction, or reversal of symptoms or the prevention of further advance of disease, debilitation and death.

#### **Diseases and disorders**

- 5                   Individuals who have diseases and disorders associated with genetic mutations may be treated by the methods of the invention. As noted above, the diseases include: cancer; heart and blood vessel diseases; peripheral blood vessel diseases; autoimmune diseases; diabetic conditions; neurodegenerative conditions; gastroenterological and hepatological diseases; mutagenic pathogen disorders; classic
- 10   hereditary diseases; disorders due to exposure to mutagenic stimuli; and other multifactorial diseases.

- The present invention allows for the treatment of multifactorial diseases. With some multifactorial diseases, it is necessary to correct several gene mutations at the same time: for example, higher than normal level of cholesterol is mainly caused by
- 15   genetic factors. While a few genes have been identified whose mutant alleles have large effects on this trait (e.g. LDLR, familial defective apoB-100), variability in cholesterol levels among individuals in most families is influenced by allelic variation in many genes (polymorphisms) as well as environmental exposures.

- Examples of cancer include: Bladder cancer; brain and CNS cancer; breast
- 20   cancer; cancer in children; colorectal, esophageal, eye tumors; head and neck; kidney cancer; leukemia; liver cancer; lung cancer; lymphoma; melanoma and other skin cancers; myeloma; pancreatic cancer; prostate cancer; sarcomas; stomach cancer; and testicular cancer. The present invention may be used to prevent metastasis and particularly effective at early stages of cancer, or in some embodiments at pre-cancerous conditions.

- 25                   Examples of heart and blood vessel diseases include: coronary heart disease; angina; heart attack; high blood pressure; congestive heart failure; cardiac arrhythmias; sudden cardiac death; heart valve disease; congenital heart defects; and stroke (usually a consequence of blood vessel disorder);

- Examples of peripheral blood vessel diseases include: peripheral arterial
- 30   diseases; arteriosclerosis obliterans; Buerger's disease; Raynaud's phenomenon; aneurysms; peripheral venous disorders: varicose veins; and phlebitis (thrombophlebitis).

09753897.010304

Examples of autoimmune diseases includes: Rheumatoid arthritis (RA), multiple sclerosis (MS), Sjogren's syndrome, sarcoidosis, autoimmune thyroiditis, reactive arthritis, ankylosing spondylitis, scleroderma, polymyositis, dermatomyositis, psoriasis, vasculitis, Wegener's granulomatosis, Crohn's disease and ulcerative colitis.

- 5           Examples of diabetic conditions include Type I and Type II diabetes. In Type I diabetes, also referred to as insulin dependent diabetes mellitus (IDDM), more than 10 different genetic markers have been found to be associated with the disease. In Type II diabetes, also referred to as adult onset or maturity-onset diabetes of the young (MODY) mutations in five different genes, which are code for glucokinase and various transcription
- 10 factors, have been found to be associated with this form of diabetes.

Examples of neurodegenerative diseases include: Huntington's disease; spinocerebellar ataxias; Alzheimer disease; amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

- Examples of gastroenterological and hepatological diseases include:
- 15 gastrointestinal malignancies, viral hepatitis, hypercholesterolaemia, alpha 1-antitrypsin deficiency; metabolic diseases of the liver and cystic fibrosis.

- Examples of mutagenic pathogen disorders include those shown to be caused by nucleic acids of viral and bacterial or fungal pathogens. The severe infections by some pathogens cause mutational changes in the body of the infected individual.
- 20 Viruses are etiological agents of many human diseases. Viral nucleic acids have a considerable homology with some human genomic sequences. During acute infections large quantities of viral nucleic acids are detected in tissue fluids and circulation. Viral infections are known to induce some mutations in humans, moreover some viruses can incorporate their sequences in human cellular DNA which causes latent, chronic and slow
- 25 hidden viral infections. Viral infections, such as rubella, result in genetic lesions causing abnormalities of early development. Human genomic DNA preparations can treat post-viral changes in cellular genome. They are likely to treat all forms of viral infections including acute, latent and chronic forms. HIV, herpes simplex virus, rabies virus, influenza virus, hepatitis A, B and C, rubella are all candidates for this treatment.

- 30           Examples of classic hereditary diseases, i.e. typical human genetic diseases, include, but are not limited to: Achondroplasia, Adult Polycystic Kidney Disorder, Alpha

09753897.010301

Zero Thalassaemia, Alpha<sub>1</sub>-Anti-trypsin Deficiency, Alpha-Thalassaemia, Beta-Thalassaemia, Color Vision Disorders, Congenital Hypothyroidism, Congenital Malformations, Cystic Fibrosis, Diabetes Mellitus, Duchenne Muscular Dystrophy, Epilepsy, Familial Hypercholesterolemia (FH), Fetal Rubella Syndrome, Fragile X Mental Retardation, Glucose-6-Phosphate Dehydrogenase Deficiency, Glutathione Deficiency, Haemoglobinopathies, Hemochromatosis, Hemophilia A and B, Huntington Disease, Inherited Thrombophilia, Neurofibromatosis, Obesity, Oculo-cutaneous Albinism, Phenylketonuria (PKU), Sickle Cell Disorders, Thalassemia, and Werding-Hoffman Disorder.

10                Examples of aging as a state of human organism which is characterized by presbyopia, loss of elasticity of skin, wrinkles, hair loss, muscle weakness, fragility of bones, gray hair, flexibility of joints, decline of sexual drive and menopause. One of the main causes of aging is gradual accumulation of mutations in cells of the body. Genomic DNA treatment can prevent and repair mutational changes in cellular genomes. This treatment has a potential to prevent and reverse aging effects in humans.

15                Examples of disorders due to exposure to mutagenic stimuli include those which result from exposure to ionizing radiation and chemical mutagen exposure.

                 Examples of other multifactorial diseases includes: dermatological disorders; urological disorders; immunological disorders such as induction of immunological compatibility at transplantations; infertility due to miscarriages; endocrinological disorders; ophthalmological disorders (cataract); otolaryngological disorders; rheumatological disorders; and gynecological disorders.

20                In some embodiments, the present invention provides the means to correct genetic mutations by replacing mutated sequences with corresponding non-mutated sequences or substitute one set of alleles for a different one. The present invention may be used to replace less desirable alleles with more desirable ones. For example, hair loss can be treated or prevented, hereditary diseases may be considered alleles rather than mutations. Other applications including cosmetic applications may also be allele-based rather than correcting mutations.

30                The methods of the invention can be applied to animal breeding. DNA preparations of animals with successful allelic composition can be prepared and amplified

09753892.010301

using this method. When injected in newborn animals or in embryos at early stages of development, these sequences can help accelerate breeding animals with the best properties.

- In some embodiments, the present invention provides the means to induce
- 5 tolerance, reduce transplant rejection and/or graft versus host disease and improve fertility by increasing tolerance/reducing rejection in the mother. In the classical work in early 1950s reported in Billingham et al. (1953) Nature 172(4379):603-606, Medawar and his colleagues found a way to induce artificial tolerance in neonatal mice at allotransplantation via injection of blood lymphocytes from donor to the recipient mouse before
- 10 transplantation. Later it was found that injections of large amounts of donor splenocytes or bone marrow cells can induce tolerance or diminish the immune response at the transplantation in adult mice. It was suggested that high dose of donor antigens injected caused deaths of lymphocyte clones responsible for the transplant rejection, but a finding that the induced tolerance was unexplainably inheritable complicated the explanation.
- 15 Recently it was suggested that immune system responds by immunization or tolerance depending of the accompanying presence of some "Danger" signal performed by specific cells (Ridge et al. 1996 Science 271(5256)1723-6).

- Immunologists consider injections of cells to recipient just as injection of some quantity of foreign antigen with following reaction of immune system, while every
- 20 lymphocyte or splenocyte carries set of genomic DNA, and the real sense of the injection may be just injection of foreign nucleic acids into the body. In the light of the theory disclosed in this application for example, the DNA from injected cells is digested partially, taken up by cells of the body and recombines in areas of homology with host DNA. This can modify some genes in cells of the body, including cells of the immune system, and
- 25 that will change the cells antigenic properties. After this, the immune system will have no choice but to consider its own cells with changed antigenic structure as proper cells of the organism. Lymphocyte clones responsible for recognition of the new antigen are probably deleted. This new property of the body will certainly have the possibility to be inherited if corresponding genes will be modified at least in part of germ cells.

- 30 For better results at allotransplantation physicians use lymphocytes or bone marrow cells injections from the future donor, although sometimes this procedure gives

00753602.010304



adverse reaction accelerating rejection. When a donor is not known, multiple blood infusions from different persons are administered, to increase allograft survival and diminish immune reaction, although this procedure can allergize the recipient and result in an adverse effect.

- 5                    Instead of whole cells, according to the present invention, either segments of donor DNA or mixed DNA segments of 10-20 healthy persons are administered. These DNA preparations are neither immunogenic, no toxic and will increase tolerance to allograft.

- 10                    At xenotransplantation of organs, for example pig's heart to a man, good results are observed when intravenous injections of pig bone marrow cells to the future transplant recipient precede the transplantation procedure. Adverse reaction sometimes results from such infusions. Using pig "DNA" will help to solve this problem and increase xenograft survival. Combined human or recipient DNA injected to a pig donor will minimize or abrogate the graft-versus-host reaction.

- 15                    According to the invention, induction of tolerance can be used to induce tolerance to allergens in those individuals who have allergies. The administration of donor DNA to an individual who has one or more allergies can introduce alleles that prevent allergic reactions when the individual is exposed to the allergen.

- Tolerance of mother to fetus may also be mediated by genetic
- 20 transformation of a mother's cells with DNA segments of a father's genome originating from sperm ejaculated during sex. Immunologists underline that effect in creation of artificial tolerance by cells injections correlate with number of injected cells to recipient. Some infertility problems or unexpected spontaneous termination of pregnancy can be caused by lack or low level of tolerance created in mother to the fetus because of
- 25 insufficient quantity of sperm cells injected to women, or problems with possible improper sperm cells degradation, breach of transportation of the DNA segments to circulation, and thus insufficient transformation of mother's cells with the delivered DNA. Such problems may be solved by treating the future mother with prepared segments of the father's DNA, or collected frozen sperm samples of the father, or , if the latter is not possible for some
- 30 reason, even injections of combined human "DNA" fragments from one or more donors.

#### **Dosage**

The dosage administered varies depending upon factors such as: pharmacodynamic characteristics; its mode and route of administration; age, health, and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment; and frequency of treatment.

- 5                   According to some embodiments of the present invention, the plurality of polynucleotide molecules are administered in an amount based on concentrations of circulating DNA and its half life. According to some embodiments of the present invention, the plurality of polynucleotide molecules are administered in an amount of 10 g per month. DNA in blood of a healthy individual approx. 2-10 ng/ml. That is, the
- 10 "normal" concentration of circulating DNA in blood is approximately 2-10 ng/ml. According to preferred embodiments of the invention, polynucleotide compositions are administered in at least a quantity sufficient to increase the normal level by approximately 10X. Depending upon the route of administration, the increase in concentration may be a 10X surge if a complete dose is administered in a short period of time, 5-10 minutes, or
- 15 elevated concentration may be maintained over a longer period of time if the DNA is infused continuously or for a period greater than about ten minutes.

In some embodiments of the present invention, DNA is administered to maintain the concentration in the range of 0.01 – 6  $\mu\text{g/ml}$ , which corresponds to 0.01 – 2  $\mu\text{M}$  concentration of a fragment with average length of 500 b.p.

- 20                   Depending upon the manner in which the plurality of polynucleotides are produced, the size distribution will vary. For the purposes of calculating dosage, the fraction of the composition which includes molecules consisting of about 200-3000 nucleotides is measured. Generally, 80% or more of polynucleotides generated by preparations described herein fall within this size distribution. It is preferred that of the
- 25 fraction of the composition which includes molecules consisting of about 200-3000 nucleotides, the average size of about 300-1000, preferably about 500 nucleotides.

- Polynucleotide compositions which comprise 0.4-16 grams of polynucleotide molecules within the 200-3000 nucleotide size distribution are preferably administered to an adult human patient. In some embodiments, the polynucleotide
- 30 compositions comprise 0.8-14 grams of polynucleotide molecules within the 200-3000 nucleotide size distribution are preferably administered to an adult human patient. In some

00753662-010301

embodiments, the polynucleotide compositions comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 grams of polynucleotide molecules within the 200-3000 nucleotide size distribution are preferably administered to an adult human patient.

In some embodiments, the polynucleotide compositions comprise 0.8-16 grams of polynucleotide molecules within the 300-1000 nucleotide size distribution are preferably administered to an adult human patient. In some embodiments, the polynucleotide compositions comprise 0.8-16 grams of polynucleotide molecules within the 300-700 nucleotide size distribution are preferably administered to an adult human patient.

Since the composition may contain polynucleotides outside the size range, the total amount of polynucleotide may be greater, i.e. up to about 20 grams or more. The dose may be delivered over a period of time, as a divided dose administered in a series of administrations over time or as a divided dose delivered at different sites by multiple routes of administration.

The pharmaceutical compositions according to this aspect of the present invention comprise about 0.4 to 20 g or more of nucleic acid molecules within the 200-3000 size distribution; in some embodiments, about 0.6 to 18 g or more of nucleic acid molecules within the 200-3000 size distribution of DNA; in some embodiments, about 0.8 to 16 g or more of nucleic acid molecules within the 200-3000 size distribution of DNA; in some embodiments, about 1 to 16 g or more of nucleic acid molecules within the 200-3000 size distribution of DNA. In some embodiments of the present invention, the pharmaceutical compositions comprise about 0.4 to 20 g or more of nucleic acid molecules within the 300-2000 size distribution; in some embodiments, about 0.6 to 18 g or more of nucleic acid molecules within the 300-2000 size distribution of DNA; in some embodiments, about 0.8 to 16 g or more of nucleic acid molecules within the 300-2000 size distribution of DNA; in some embodiments, about 1 to 16 g or more of nucleic acid molecules within the 300-2000 size distribution of DNA. In some embodiments, the pharmaceutical compositions according to this aspect of the present invention comprise about 0.4 to 20 g or more of nucleic acid molecules within the 300-1000 size distribution; in some embodiments, about 0.6 to 18 g or more of nucleic acid molecules within the 300-1000 size distribution of DNA; in some embodiments, about 0.8 to 16 g or more of nucleic

00753802.010301

acid molecules within the 300-1000 size distribution of DNA; in some embodiments, about 1 to 16 g or more of nucleic acid molecules within the 300-1000 size distribution of DNA.

In some embodiments, the calculation of DNA dosage is as follows:

- 5 3 ml of human sperm = about 1 mg human sperm DNA
- $$(3 \text{ ml sperm}) \times (70 \times 10^6 \text{ cells/ml}) \times (5 \times 10^{-12} \text{ g [amount of DNA in each spermatozoid]})$$
- $$= \text{about } 200 \times 5 \times 10^6 \times 10^{-12} = 1000 \times 10^{-6} \text{ g} = 1 \text{ mg human sperm DNA.}$$
- 10 If multiplied by 10,000 (by PCR) = 10 g DNA can be prepared from a 3ml sample.
- 10g DNA /  $10 \times 10^{-12}$  g DNA/cell =  $10^{12}$  cells ;  $10^{12} \times 2000 \mu\text{m}^3$  (volume of embryo fibroblasts) = 2 kg

We have roughly estimated quantities in which cells are distributed in the human organism taking into account the fact that in some tissues there are very few or no

- 15 cells or there are few cells that actively participate in DNA circulation in the organism.
- The human body of 70 kg equals:

- 1) skin + skin fat - 20 kg (eqv. 0.2 kg cells)
  - 2) Bones + connective tissues+ tendons - 30 kg (0.2 kg cells)
  - 20 3) Blood - 7 kg ( 0.07 kg cells)
  - 4) Muscles - 10 kg 1/20 (0.5 kg cells)
  - 5) Intestine - 3 kg 1/10 (0.3 kg cells)
  - 6) liver 1 kg 1/2 (0.5 kg cells)
  - 7) Brain 1 kg 1/4 (0.25 kg cells)
  - 25 8) Other glands 1 kg (0.25 kg cells)
- Total cells 2.3 kg

### Routes of administration

- According to the present invention, the polynucleotide molecules may be delivered to the individual by any means and mode of administration that will result in the
- 30 polynucleotides being taken up by cells which contain the genetic mutation associated with the disease or disorder to be treated. In some preferred embodiments, the polynucleotide

09753692-010301

- molecules are administered by: intravenous injection; intramuscular injection; intradermal injection; subcutaneous delivery; intraperitoneal delivery; topical or lavage delivery by application onto different mucosa and/or skin; ingestion per os (with or without stomach neutralization pretreatment or enteric-coating formulation); per rectum; intravaginally;
- 5 intraocularly; intranasally, intratumorally; intracerebrally, intraocular injection, by inhalation and by delivery to the spinal cord.

In some applications, particularly cosmetic applications such as for treatment of hair loss or age-damaged and/or sun-damaged skin, topical administration is preferred.

- 10 The devices and apparatus used can be any of those which are useful to administer the polynucleotide composition by the chosen route of administration. In the case of injections, in addition to syringes, in some embodiments, high powered needleless injection devices or projectile bombardment devices may be used.

- Those skilled in the art will perform administration by well known methods
- 15 including appropriate preparatory and follow up examination.

### **Regimen**

- According to the present invention, the polynucleotide molecules may be delivered to the individual by any administration regimen that will maintain sufficient polynucleotide presence such that polynucleotides will be taken up by cells at a level
- 20 effective to correct genetic mutations. In some preferred embodiments, the polynucleotide molecules are administered continuously. In some embodiments, the polynucleotide molecules are administered hourly. In some embodiments, the polynucleotide molecules are administered daily. In some embodiments, the polynucleotide molecules are administered every other day. In some embodiments, the polynucleotide molecules are
- 25 administered weekly. In some embodiment, the polynucleotide molecules are administered over the course of 1-26 weeks, preferably 2-13 weeks, preferably 2-8 week, preferably 2-6 weeks and, in some embodiments, more preferably 2-4 weeks..

### **Formulations**

- Formulations comprising the polynucleotide molecules are made up
- 30 according to the mode and site of administration. Such formulation is well within the skill in the art. In addition to nucleic acid molecules, the formulation may also include buffers,

05753892.010301

excipients, stabilizers, carriers and diluents. Suitable pharmaceutical carriers are described in the most recent edition of *Remington's Pharmaceutical Sciences*, A. Osol, a standard reference text in this field which is incorporated herein by reference.

For parenteral administration, the composition can be, for example,  
5 formulated as a solution, suspension, emulsion or lyophilized powder in association with a pharmaceutically acceptable parenteral vehicle. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils may also be used. The vehicle or lyophilized powder may contain additives that maintain isotonicity (e.g., sodium chloride, mannitol)  
10 and chemical stability (e.g., buffers and preservatives). The formulation is sterilized by commonly used techniques.

The pharmaceutical compositions according to this aspect of the present invention are formulated according to the mode of administration to be used. In cases where injection is the chosen mode of administration, a sterile, isotonic, non-pyrogenic  
15 formulation is used. Generally, additives for isotonicity can include sodium chloride, dextrose, mannitol, sorbitol and lactose. Isotonic solutions such as phosphate buffered saline are preferred. Stabilizers include gelatin and albumin.

DNA can be in the form of real solution as sodium or lithium salt or as complexes with basic proteins such as histones or protamines, or synthetic polycations, or  
20 precipitates like calcium phosphate, or can be absorbed on carriers such as hydroxylapatite or some anion exchangers. The DNA may be complexed with either synthetic or natural nuclear proteins or both. Further, it may be single- or double-stranded, linear or circular, relaxed or supercoiled.

For administration in the form of suppository DNA can also be  
25 formulated as mentioned above (solution, suspension, emulsion, dry powder) in combination with conventionally used inactive base including for instance cocoa butter, starch, methylparaben, propylparaben.

For topical application on skin DNA with commonly used inactive ingredients for lotions, creams and ointments, such as mineral or vegetable oil, propylene  
30 Glycol, PEG-Stearate, lecitin, EDTA, methyl/ethylparaben.

For administration in low prophylactic doses DNA solutions in composition

09753892-010201

of lozenges or tablets for dissolving in mouth.

### Source

The plurality of polynucleotide molecules may be obtained by processing genomic DNA from a number of sources. In some embodiments, autologous DNA (self donor) that is collected at the patient's young age or at least before the disease or exposure to irradiation or chemical mutagens is used. In such embodiments, genomic DNA may be "banked" from birth or a young age. According to the invention banked collections of DNA samples may be stored in preparation for use according to the invention. In some embodiments, allogenic DNA, such as from living donors or corpses, is used. In such 5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000  
1005  
1010  
1015  
1020  
1025  
1030  
1035  
1040  
1045  
1050  
1055  
1060  
1065  
1070  
1075  
1080  
1085  
1090  
1095  
1100  
1105  
1110  
1115  
1120  
1125  
1130  
1135  
1140  
1145  
1150  
1155  
1160  
1165  
1170  
1175  
1180  
1185  
1190  
1195  
1200  
1205  
1210  
1215  
1220  
1225  
1230  
1235  
1240  
1245  
1250  
1255  
1260  
1265  
1270  
1275  
1280  
1285  
1290  
1295  
1300  
1305  
1310  
1315  
1320  
1325  
1330  
1335  
1340  
1345  
1350  
1355  
1360  
1365  
1370  
1375  
1380  
1385  
1390  
1395  
1400  
1405  
1410  
1415  
1420  
1425  
1430  
1435  
1440  
1445  
1450  
1455  
1460  
1465  
1470  
1475  
1480  
1485  
1490  
1495  
1500  
1505  
1510  
1515  
1520  
1525  
1530  
1535  
1540  
1545  
1550  
1555  
1560  
1565  
1570  
1575  
1580  
1585  
1590  
1595  
1600  
1605  
1610  
1615  
1620  
1625  
1630  
1635  
1640  
1645  
1650  
1655  
1660  
1665  
1670  
1675  
1680  
1685  
1690  
1695  
1700  
1705  
1710  
1715  
1720  
1725  
1730  
1735  
1740  
1745  
1750  
1755  
1760  
1765  
1770  
1775  
1780  
1785  
1790  
1795  
1800  
1805  
1810  
1815  
1820  
1825  
1830  
1835  
1840  
1845  
1850  
1855  
1860  
1865  
1870  
1875  
1880  
1885  
1890  
1895  
1900  
1905  
1910  
1915  
1920  
1925  
1930  
1935  
1940  
1945  
1950  
1955  
1960  
1965  
1970  
1975  
1980  
1985  
1990  
1995  
2000  
2005  
2010  
2015  
2020  
2025  
2030  
2035  
2040  
2045  
2050  
2055  
2060  
2065  
2070  
2075  
2080  
2085  
2090  
2095  
2100  
2105  
2110  
2115  
2120  
2125  
2130  
2135  
2140  
2145  
2150  
2155  
2160  
2165  
2170  
2175  
2180  
2185  
2190  
2195  
2200  
2205  
2210  
2215  
2220  
2225  
2230  
2235  
2240  
2245  
2250  
2255  
2260  
2265  
2270  
2275  
2280  
2285  
2290  
2295  
2300  
2305  
2310  
2315  
2320  
2325  
2330  
2335  
2340  
2345  
2350  
2355  
2360  
2365  
2370  
2375  
2380  
2385  
2390  
2395  
2400  
2405  
2410  
2415  
2420  
2425  
2430  
2435  
2440  
2445  
2450  
2455  
2460  
2465  
2470  
2475  
2480  
2485  
2490  
2495  
2500  
2505  
2510  
2515  
2520  
2525  
2530  
2535  
2540  
2545  
2550  
2555  
2560  
2565  
2570  
2575  
2580  
2585  
2590  
2595  
2600  
2605  
2610  
2615  
2620  
2625  
2630  
2635  
2640  
2645  
2650  
2655  
2660  
2665  
2670  
2675  
2680  
2685  
2690  
2695  
2700  
2705  
2710  
2715  
2720  
2725  
2730  
2735  
2740  
2745  
2750  
2755  
2760  
2765  
2770  
2775  
2780  
2785  
2790  
2795  
2800  
2805  
2810  
2815  
2820  
2825  
2830  
2835  
2840  
2845  
2850  
2855  
2860  
2865  
2870  
2875  
2880  
2885  
2890  
2895  
2900  
2905  
2910  
2915  
2920  
2925  
2930  
2935  
2940  
2945  
2950  
2955  
2960  
2965  
2970  
2975  
2980  
2985  
2990  
2995  
3000  
3005  
3010  
3015  
3020  
3025  
3030  
3035  
3040  
3045  
3050  
3055  
3060  
3065  
3070  
3075  
3080  
3085  
3090  
3095  
3100  
3105  
3110  
3115  
3120  
3125  
3130  
3135  
3140  
3145  
3150  
3155  
3160  
3165  
3170  
3175  
3180  
3185  
3190  
3195  
3200  
3205  
3210  
3215  
3220  
3225  
3230  
3235  
3240  
3245  
3250  
3255  
3260  
3265  
3270  
3275  
3280  
3285  
3290  
3295  
3300  
3305  
3310  
3315  
3320  
3325  
3330  
3335  
3340  
3345  
3350  
3355  
3360  
3365  
3370  
3375  
3380  
3385  
3390  
3395  
3400  
3405  
3410  
3415  
3420  
3425  
3430  
3435  
3440  
3445  
3450  
3455  
3460  
3465  
3470  
3475  
3480  
3485  
3490  
3495  
3500  
3505  
3510  
3515  
3520  
3525  
3530  
3535  
3540  
3545  
3550  
3555  
3560  
3565  
3570  
3575  
3580  
3585  
3590  
3595  
3600  
3605  
3610  
3615  
3620  
3625  
3630  
3635  
3640  
3645  
3650  
3655  
3660  
3665  
3670  
3675  
3680  
3685  
3690  
3695  
3700  
3705  
3710  
3715  
3720  
3725  
3730  
3735  
3740  
3745  
3750  
3755  
3760  
3765  
3770  
3775  
3780  
3785  
3790  
3795  
3800  
3805  
3810  
3815  
3820  
3825  
3830  
3835  
3840  
3845  
3850  
3855  
3860  
3865  
3870  
3875  
3880  
3885  
3890  
3895  
3900  
3905  
3910  
3915  
3920  
3925  
3930  
3935  
3940  
3945  
3950  
3955  
3960  
3965  
3970  
3975  
3980  
3985  
3990  
3995  
4000  
4005  
4010  
4015  
4020  
4025  
4030  
4035  
4040  
4045  
4050  
4055  
4060  
4065  
4070  
4075  
4080  
4085  
4090  
4095  
4100  
4105  
4110  
4115  
4120  
4125  
4130  
4135  
4140  
4145  
4150  
4155  
4160  
4165  
4170  
4175  
4180  
4185  
4190  
4195  
4200  
4205  
4210  
4215  
4220  
4225  
4230  
4235  
4240  
4245  
4250  
4255  
4260  
4265  
4270  
4275  
4280  
4285  
4290  
4295  
4300  
4305  
4310  
4315  
4320  
4325  
4330  
4335  
4340  
4345  
4350  
4355  
4360  
4365  
4370  
4375  
4380  
4385  
4390  
4395  
4400  
4405  
4410  
4415  
4420  
4425  
4430  
4435  
4440  
4445  
4450  
4455  
4460  
4465  
4470  
4475  
4480  
4485  
4490  
4495  
4500  
4505  
4510  
4515  
4520  
4525  
4530  
4535  
4540  
4545  
4550  
4555  
4560  
4565  
4570  
4575  
4580  
4585  
4590  
4595  
4600  
4605  
4610  
4615  
4620  
4625  
4630  
4635  
4640  
4645  
4650  
4655  
4660  
4665  
4670  
4675  
4680  
4685  
4690  
4695  
4700  
4705  
4710  
4715  
4720  
4725  
4730  
4735  
4740  
4745  
4750  
4755  
4760  
4765  
4770  
4775  
4780  
4785  
4790  
4795  
4800  
4805  
4810  
4815  
4820  
4825  
4830  
4835  
4840  
4845  
4850  
4855  
4860  
4865  
4870  
4875  
4880  
4885  
4890  
4895  
4900  
4905  
4910  
4915  
4920  
4925  
4930  
4935  
4940  
4945  
4950  
4955  
4960  
4965  
4970  
4975  
4980  
4985  
4990  
4995  
5000  
5005  
5010  
5015  
5020  
5025  
5030  
5035  
5040  
5045  
5050  
5055  
5060  
5065  
5070  
5075  
5080  
5085  
5090  
5095  
5100  
5105  
5110  
5115  
5120  
5125  
5130  
5135  
5140  
5145  
5150  
5155  
5160  
5165  
5170  
5175  
5180  
5185  
5190  
5195  
5200  
5205  
5210  
5215  
5220  
5225  
5230  
5235  
5240  
5245  
5250  
5255  
5260  
5265  
5270  
5275  
5280  
5285  
5290  
5295  
5300  
5305  
5310  
5315  
5320  
5325  
5330  
5335  
5340  
5345  
5350  
5355  
5360  
5365  
5370  
5375  
5380  
5385  
5390  
5395  
5400  
5405  
5410  
5415  
5420  
5425  
5430  
5435  
5440  
5445  
5450  
5455  
5460  
5465  
5470  
5475  
5480  
5485  
5490  
5495  
5500  
5505  
5510  
5515  
5520  
5525  
5530  
5535  
5540  
5545  
5550  
5555  
5560  
5565  
5570  
5575  
5580  
5585  
5590  
5595  
5600  
5605  
5610  
5615  
5620  
5625  
5630  
5635  
5640  
5645  
5650  
5655  
5660  
5665  
5670  
5675  
5680  
5685  
5690  
5695  
5700  
5705  
5710  
5715  
5720  
5725  
5730  
5735  
5740  
5745  
5750  
5755  
5760  
5765  
5770  
5775  
5780  
5785  
5790  
5795  
5800  
5805  
5810  
5815  
5820  
5825  
5830  
5835  
5840  
5845  
5850  
5855  
5860  
5865  
5870  
5875  
5880  
5885  
5890  
5895  
5900  
5905  
5910  
5915  
5920  
5925  
5930  
5935  
5940  
5945  
5950  
5955  
5960  
5965  
5970  
5975  
5980  
5985  
5990  
5995  
6000  
6005  
6010  
6015  
6020  
6025  
6030  
6035  
6040  
6045  
6050  
6055  
6060  
6065  
6070  
6075  
6080  
6085  
6090  
6095  
6100  
6105  
6110  
6115  
6120  
6125  
6130  
6135  
6140  
6145  
6150  
6155  
6160  
6165  
6170  
6175  
6180  
6185  
6190  
6195  
6200  
6205  
6210  
6215  
6220  
6225  
6230  
6235  
6240  
6245  
6250  
6255  
6260  
6265  
6270  
6275  
6280  
6285  
6290  
6295  
6300  
6305  
6310  
6315  
6320  
6325  
6330  
6335  
6340  
6345  
6350  
6355  
6360  
6365  
6370  
6375  
6380  
6385  
6390  
6395  
6400  
6405  
6410  
6415  
6420  
6425  
6430  
6435  
6440  
6445  
6450  
6455  
6460  
6465  
6470  
6475  
6480  
6485  
6490  
6495  
6500  
6505  
6510  
6515  
6520  
6525  
6530  
6535  
6540  
6545  
6550  
6555  
6560  
6565  
6570  
6575  
6580  
6585  
6590  
6595  
6600  
6605  
6610  
6615  
6620  
6625  
6630  
6635  
6640  
6645  
6650  
6655  
6660  
6665  
6670  
6675  
6680  
6685  
6690  
6695  
6700  
6705  
6710  
6715  
6720  
6725  
6730  
6735  
6740  
6745  
6750  
6755  
6760  
6765  
6770  
6775  
6780  
6785  
6790  
6795  
6800  
6805  
6810  
6815  
6820  
6825  
6830  
6835  
6840  
6845  
6850  
6855  
6860  
6865  
6870  
6875  
6880  
6885  
6890  
6895  
6900  
6905  
6910  
6915  
6920  
6925  
6930  
6935  
6940  
6945  
6950  
6955  
6960  
6965  
6970  
6975  
6980  
6985  
6990  
6995  
7000  
7005  
7010  
7015  
7020  
7025  
7030  
7035  
7040  
7045  
7050  
7055  
7060  
7065  
7070  
7075  
7080  
7085  
7090  
7095  
7100  
7105  
7110  
7115  
7120  
7125  
7130  
7135  
7140  
7145  
7150  
7155  
7160  
7165  
7170  
7175  
7180  
7185  
7190  
7195  
7200  
7205  
7210  
7215  
7220  
7225  
7230  
7235  
7240  
7245  
7250  
7255  
7260  
7265  
7270  
7275  
7280  
7285  
7290  
7295  
7300  
7305  
7310  
7315  
7320  
7325  
7330  
7335  
7340  
7345  
7350  
7355  
7360  
7365  
7370  
7375  
7380  
7385  
7390  
7395  
7400  
7405  
7410  
7415  
7420  
7425  
7430  
7435  
7440  
7445  
7450  
7455  
7460  
7465  
7470  
7475  
7480  
7485  
7490  
7495  
7500  
7505  
7510  
7515  
7520  
7525  
7530  
7535  
7540  
7545  
7550  
7555  
7560  
7565  
7570  
7575  
7580  
7585  
7590  
7595  
7600  
7605  
7610  
7615  
7620  
7625  
7630  
7635  
7640  
7645  
7650  
7655  
7660  
7665  
7670  
7675  
7680  
7685  
7690  
7695  
7700  
7705  
7710  
7715  
7720  
7725  
7730  
7735  
7740  
7745  
7750  
7755  
7760  
7765  
7770  
7775  
7780  
7785  
7790  
7795  
7800  
7805  
7810  
7815  
7820  
7825  
7830  
7835  
7840  
7845  
7850  
7855  
7860  
7865  
7870  
7875  
7880  
7885  
7890  
7895  
7900  
7905  
7910  
7915  
7920  
7925  
7930  
7935  
7940  
7945  
7950  
7955  
7960  
7965  
7970  
7975  
7980  
7985  
7990  
7995  
8000  
8005  
8010  
8015  
8020  
8025  
8030  
8035  
8040  
8045  
8050  
8055  
8060  
8065  
8070  
8075  
8080  
8085  
8090  
8095  
8100  
8105  
8110  
8115  
8120  
8125  
8130  
8135  
8140  
8145  
8150  
8155  
8160  
8165  
8170  
8175  
8180  
8185  
8190  
8195  
8200  
8205  
8210  
8215  
8220  
8225  
8230  
8235  
8240  
8245  
8250  
8255  
8260  
8265  
8270  
8275  
8280  
8285  
8290  
8295  
8300  
8305  
8310  
8315  
8320  
8325  
8330  
8335  
8340  
8345  
8350  
8355  
8360  
8365  
8370  
8375  
8380  
8385  
8390  
8395  
8400  
8405  
8410  
8415  
8420  
8425  
8430  
8435  
8440  
8445  
8450  
8455  
8460  
8465  
8470  
8475  
8480  
8485  
8490  
8495  
8500  
8505  
8510  
8515  
8520  
8525  
8530  
8535  
8540  
8545  
8550  
8555  
8560  
8565  
8570  
8575  
8580  
8585  
8590  
8595  
8600  
8605  
8610  
8615  
8620  
8625  
8630  
8635  
8640  
8645  
8650  
8655  
8660  
8665  
8670  
8675  
8680  
8685  
8690  
8695  
8700  
8705  
8710  
8715  
8720  
8725  
8730  
8735  
8740  
8745  
8750  
8755  
8760  
8765  
8770  
8775  
8780  
8785  
8790  
8795  
8800  
8805  
8810  
8815  
8820  
8825  
8830  
8835  
8840  
8845  
8850  
8855  
8860  
8865  
8870  
8875  
8880  
8885  
8890  
8895  
8900  
8905  
8910  
8915  
8920  
8925  
8930  
8935  
8940  
8945  
8950  
8955  
8960  
8965  
8970  
8975  
8980  
8985  
8990  
8995  
9000  
9005  
9010  
9015  
9020  
9025  
9030  
9035  
9040  
9045  
9050  
9055  
9060  
9065  
9070  
9075  
9080  
9085  
9090  
9095  
9100  
9105  
9110  
9115  
9120  
9125  
9130  
9135  
9140  
9145  
9150  
9155  
9160  
9165  
9170  
9175  
9180  
9185  
9190  
9195  
9200  
9205  
9210  
9215  
9220  
9225  
9230  
9235  
9240  
9245  
9250  
9255  
9260  
9265  
9270  
9275  
9280  
9285  
9290  
9295  
9300  
9305  
9310  
9315  
9320  
9325  
9330  
9335  
9340  
9345  
9350  
9355  
9360  
9365  
9370  
9375  
9380  
9385  
9390  
9395  
9400  
9405  
9410  
9415  
9420  
9425  
9430  
9435  
9440  
9445  
9450  
9455  
9460  
9465  
9470  
9475  
9480  
9485  
9490  
9495  
9500  
9505  
9510  
9515  
9520  
9525  
9530  
9535  
9540  
9545  
9550  
9555  
9560  
9565  
9570  
9575  
9580  
9585  
9590  
9595  
9600  
9605  
9610  
9615  
9620  
9625  
9630  
9635  
9640  
9645  
9650  
9655  
9660  
9665  
9670  
9675  
9680  
9685  
9690  
9695  
9700  
9705  
9710  
9715  
9720  
9725  
9730  
9735  
9740  
9745  
9750  
9755  
9760  
9765  
9770  
9775  
9780  
9785  
9790  
9795  
9800  
9805  
9810  
9815  
9820  
9825  
9830  
9835  
9840  
9845  
9850  
9855  
9860  
9865  
9870  
9875  
9880  
9885  
9890  
9895  
9900  
9905  
9910  
9915  
9920  
9925  
9930  
9935  
9940  
9945  
9950  
9955  
9960  
9965  
9970  
9975  
9980  
9985  
9990  
9995  
10000  
10005  
10010  
10015  
10020  
10025  
10030  
10035  
10040  
10045  
10050  
10055  
10060  
10065  
10070  
10075  
10080  
10085  
10090  
10095  
10100  
10105  
10110  
10115  
10120  
10125  
10130  
10135  
10140  
10145  
10150  
10155  
10160  
10165  
10170  
10175  
10180  
10185  
10190  
101

with degenerative primers.

For example, random primer PCR mainly according to Telenius et al (1992) Genomics 13:718-725 which is incorporated herein by reference. Telenius reports 18-mer partially degenerative DOP oligonucleotide primers for random DNA amplification. The  
5 typical protocol is as follows: PCR buffer with 0.2 mM  $MgCl_2$ , 0.2 mM NTP, 2  $\mu$ M DOP 6-MW, 40 U/ml Taq polymerase. Cycler: 95°C 5'; 10" 94°C, 10" 53°C, 30" 72°C (the latter three steps are repeated 30 times), 10' 72°C. Using 1 ng of the DNA in a 50  $\mu$ l reaction mixture we can get up to 10  $\mu$ g DNA fragments 200-3000 bp in length. A one liter mixture yields 0.2 g DNA; a 10 liter mixture yields 2 g DNA. For 1 liter mixtures we need  
10 40,000 U Taq polymerase, 100 ml 2 mM NTP (100 mg NTP), 20 ml 100  $\mu$ M DOP 6 M-W (2  $\mu$ mol).

### Compositions

Another aspect of the invention relates to pharmaceutical compositions that comprise, in a pharmaceutically acceptable carrier a plurality of polynucleotide molecules  
15 which collectively comprise an essentially complete genome in polynucleotide molecules having about 100-3000 nucleotides.

In some embodiments, the compositions contain 0.01 – 16 g of polynucleotides having 200-3000 nucleotides each. In some embodiments, the compositions contain 0.01 – 16 g of polynucleotides having 200-3000 nucleotides each with an average length of 300  
20 -1000 nucleotides. In some embodiments, the compositions contain 0.01 – 16 g of polynucleotides having 200-3000 nucleotides each with an average length of 500 nucleotides. In some embodiments, the compositions contains 0.04 – 16 g of polynucleotides having 200-3000 nucleotides each. In some embodiments, the compositions contain 0.4 – 16 g of polynucleotides having 200-3000 nucleotides each.

In some embodiments, the compositions contain at least 80% of polynucleotide molecules administered are about 200-3000 nucleotides in length. In some embodiments, the compositions contain at least 80% of polynucleotide molecules administered are about 200-3000 nucleotides in length and have an average length of about 300-1000. In some  
25 embodiments, the compositions contain at least 80% of polynucleotide molecules administered are about 200-3000 nucleotides in length and have an average length of about 500. In some embodiments, the compositions contain at least 80% of polynucleotide  
30

09753602-010304



molecules administered are about 300-2000 nucleotides in length. In some embodiments, the compositions contain at least 80% of polynucleotide molecules administered are about 300-2000 nucleotides in length and have an average length of about 500. In some embodiments, the compositions contain at least 80% of polynucleotide molecules

- 5 administered are 300-1000 nucleotides in length. In some embodiments, the compositions contain at least 80% of polynucleotide molecules administered are 300-1000 nucleotides in length and have an average length of 500.

In some embodiments, the pharmaceutical compositions are suitable for injection, i.e. sterile and pyrogen free.

10 **EXAMPLE**

The foregoing examples are meant to illustrate the invention and are not to be construed to limit the invention in any way. Those skilled in the art will recognize modifications that are within the spirit and scope of the invention. All references cited herein are hereby incorporated by reference in their entirety.

15 **Example 1. Preparations of human DNA in cell medium change the pattern of specific protein expression in human cancer cells in culture.**

- Example 1 demonstrates a capability of DNA preparations prepared from healthy donor sperm cells to influence differential expression of specific cell proteins in human tumor cell lines: breast tumor, BT474, ovarian carcinoma OVCAR5 and promyelocytic
- 20 leukemia HL60. The breast tumor cells are adhesive epithelial type cells forming a monolayer with multilayer cell clumps; OVCAR5 are fibroblastoid type cells forming a monolayer and HL60 cells are spherical cells that grow in suspension.

Two types of preparations were used:

- 1) purified total chromatin prepared from sperm cells and fragmented by
- 25 nuclease digestion to oligonucleosome size (Wagner, et al. Arch. Androl. (1981) 7(3):251-7, which is incorporated herein by reference) (DNA lengths 200-3000 bp).
- 2) genomic DNA isolated from sperm cells (using Amersham-Pharmacia 'genomic DNA isolation' kit and procedure modified by addition of a reducing agent

(DTT) to lysis buffer) mildly sonicated to obtain 200-3000 bp size fragments.

Cells were plated in 24-well plates for tissue culture at a density of 100,000 cells per well and cultured in RPMI 1640 with addition of 5% fetal calf serum and Pen/strep antibiotics at 37°C in the presence of 5% CO<sub>2</sub> in humidified air.

- 5           2 µg of DNA preparations either in the form of DNA solution or as chromatin fragments were added in 20 µl of PBS to all experimental wells, and 20 µl of PBS were added to control wells. The quantity of 2 µg of DNA was chosen in order to provide excess of extracellular DNA over cellular DNA in each well, so that cellular DNA would have a possibility to recombine with extracellular DNA in such manner that all cellular genes
- 10 (cancerous, normal or mutated) could have a good chance to be substituted at least in part with fragments of normal human extracellular DNA. The medium in wells was changed every 3 days and fresh DNA preparations were also added every 3 days for 2 weeks. Following this incubation period, medium was removed and cells were washed with cold PBS 3 times. Cells were then removed from wells, collected by centrifugation and lysed
- 15 in sample loading buffer containing 2% SDS, 20% sucrose, 3mM DTT with incubation of samples on a boiling water bath for 3 min. Samples were resolved in SDS-PAGE and proteins were visualized using an immunoblotting procedure.

- The results are shown in Figures 1A and 1B. Figures 1A and 1B show that the expression levels of epidermal growth factor family protein erbB2, which is overexpressed
- 20 considerably in many different types of cancer, dropped down as a result of DNA treatment in OVCAR5 and BT474 cells. In the cell lines OVCAR5 and HL60 our DNA preparations induced considerable downregulation of protein cyclin D1 whose overexpression in cancer cells often correlates with increased proliferation. In contrast, the treatment does not reduce cyclin D1 levels in BT474 cells and may even cause a slight
- 25 increase. It is noteworthy that BT474 cells are slowly proliferating cells, and may require only a minimal level of cyclin D1 expression that cannot be reduced. The experimental effect appears more pronounced when DNA in complex with basic nuclear proteins (fragmented chromatin) was used as DNA preparation. This can be explained by lesser accessibility of such complexes to nuclease attack in medium or in some cellular
- 30 compartments. It may also may be due to easier cellular uptake of such complexes. It should also be noted that the choice of two weeks time exposure of cells to extracellular

09753892.010301

DNA in this experiment was based on preliminary experiments in which we found that treatment with the DNA preparations had no visible toxic effect on cells for at least ten days or more. Furthermore no changes in differential protein expression could be found during first ten days of the experiment. In the following few days (depending on dose) changes in protein expression started to occur, but beyond 20 days, the cells changed their properties so much that it became difficult to maintain cell culture. For example, in BT474 cells the most developed effects were observed in wells with fragmented chromatin; on day 15-16 of the experiment the number of cells in these wells decreased two times compared to the control wells because of the retardation in cell division and death of some cells. Stopping addition of DNA preparations after the 2 weeks' treatment did not help cells detectably: they grew slower and slower. The cells treated with naked DNA also stopped growing, similar to the cells treated with chromatin fragments. We replated these cells, and they attached to plastic, but did not grow well. After a month of such cultivation they were still alive, but did not form a monolayer and their number gradually decreased. This whole pattern looks like the desired solution of many anticancer projects: either make cancer cells die or stop proliferating. Genomic DNA treatment appears to achieve that goal.

**Example 2. Introduction of changes into cellular genomic DNA in living mice.  
Induction of artificial tolerance in recipient mice to a donor allograft.**

CBA and A/He are immunologically distinct mouse strains, and A/He allografts to CBA are never accepted but are always quickly rejected (Kaledin, et al. 1974 Conf. of the Res. Lab. of Exp. Biol. Models (Abstracts) Acad. Med. Sci, Moscow USSR p 5-52). The example demonstrates induction of immunological tolerance in CBA mice via injection of appropriate amounts of donor DNA preparations. The supposed mechanism of such induction is that injected donor DNA is substituting responsible alleles in CBA recipient cells to A/He specific alleles. This substitution will result in emergence of A/He antigens on CBA cells, which is probably followed by negative selection of lymphocyte clones normally responsible for the rejection.

A/He mouse strain specific hepatoma A, which is unable to grow in CBA mice mainly because of immunologic incompatibility, was used as tumor allograft for

allotransplantation in treated and control CBA mice.  $10^6$  tumor cells were inoculated subcutaneously in the lateral part of the hind leg of the recipient CBA mice. The administration of that number of cells results in tumor growth in 100% of the A/He mice over the time of 1 to 2 weeks. This treatment never leads to formation of tumor in CBA mice (Kaledin, et al. 1974 *supra*). DNA isolated from A/He mice liver and mildly sonicated to obtain fragments with lengths between 200 and 3000 bp and A/He mice liver purified chromatin digested with micrococcal nuclease to oligonucleosome size fragments with DNA length between 200 and 3000 bp were injected i.p. in CBA mice according to three different schemes:

- 10                   a single i.p. injection of either DNA or chromatin preparation (40  $\mu$ g of DNA per injection in the form DNA and chromatin) on the second day after birth;
- a series of 4 injections of either DNA or chromatin preparation (40  $\mu$ g of DNA per injection in the from of DNA or chromatin) every 5 days starting with the second day after birth;
- 15                   a series of 3 injections of chromatin (40  $\mu$ g of DNA per injection) every 5 days starting from the 6<sup>th</sup> day after birth;
- control groups received injections of physiological salt solution.

- Hepatoma A tumors were inoculated into treated and control mice 25 days after a single injection, or one week after the last injection in multi-injectional therapy. Two
- 20   weeks later, approximately 30% of mice that received DNA preparations developed cancer at the site of inoculation. No cancer developed in control groups of mice. It seemed that the DNA in chromatin fragments was slightly more effective in this experiment. In the following next two weeks, the percentage of mice that developed cancer increased to approximately 50% in treated mice.

- 25                   Although immune incompatibility is considered to be the main cause of rejection of hepatoma A tumor by CBA mice, there are probably other factors that interfere with the tumor acceptance. Usually after allotransplantation one can see healing of seams and wounds during the first 10-12 days before the immune response is developed. Then the immune system rejects the allograft. The inoculation of  $10^6$  of tumor cells to the A/He
- 30   mouse strain resulted in solid tumor development 7-14 days after the treatment, so if the inoculated tumor cells proliferated at the same rate in CBA mice, then at least a small

09753692.010301

tumor should have appeared in the inoculation site before development of the immune response. It did not happen which means that not only immune problems but some other factors or their absence prevented tumor development in the CBA mice soon after the inoculation. If the latter assumption is true then the genomic DNA therapy enables both:

5 creation of the transplantational tolerance and supplying of the CBA mice with some missing, A/He specific factors that are required for hepatoma A proliferation.

### Example 3. Random human genomic DNA amplification in PCR reaction.

We used a random primer PCR procedure mainly according to Telenius et al (1992) *supra* with modifications. Telenius's 18-mer partially degenerated DOP 6-MW

10 oligonucleotide primer was used for random DNA amplification. The typical protocol was as follows: PCR buffer with 0.2 mM  $MgCl_2$ , 0.2 mM NTP, 2  $\mu M$  DOP 6-MW, 40 U/ml Taq polymerase. Cycler: 95°C 5'; 10" 94°C, 10" 53°C, 30" 72°C (the latter three steps are repeated 30 times), 10' 72°C. Using 1 ng of the DNA in a 50  $\mu l$  reaction mixture we can get up to 10  $\mu M$  DNA fragments 200-3000 bp in length. 1 liter mixtures yields 0.2 g DNA,

15 10 liter mixtures yields 2 g DNA. For 1 liter mixtures we need about 40,000 U Taq polymerase, 100 ml 2 mM NTP (100 mg NTP), 20 ml 100  $\mu M$  DOP 6 M-W (2  $\mu mol$ ).

### Example 4

The present invention includes an apparatus for doing large scale PCR preparations. The apparatus comprises a reaction tube, at least one pump for continuously

20 supplying of reagents to the reaction tube, four temperature chambers, and a collection vessel. The reagents are combined and enter the reaction tube by action of the pump. In some embodiments, there are two supply pumps which combine various components into a mixing vessel which then communicates with the reaction tube. The reaction solution flows through the reaction tube through a series of reaction tube lengths which alternately

25 pass through each of the four temperature chambers to produce a cycle segment. That is, the reaction solution flows through the reaction tube which passes through each of the four temperature chambers. The portion of the reaction tube which passes through each of the four temperature chambers is referred to as a cycle segment and the flow of the reaction solution through a cycle segment corresponds to a cycle. The reaction tube comprises at

least twenty consecutive cycle segments. That is the reaction tube emerges from the fourth chamber and reenters the first chamber at least twenty times. In preferred embodiments, the reaction tube comprises at least thirty consecutive cycle segments, in some preferred embodiments, the reaction tube comprises at least forty consecutive cycle segments.

- 5 In a preferred embodiment the genomic DNA is manufactured as copies using random PCR with partially degenerate primers. As discussed above, in some embodiments such as for example those involving severe genomic diseases, the total dosage for a course of treatment (for a few months) may comprise 10-20 g of DNA. For manufacturing of such amounts of DNA special large scale PCR apparatus is designed and
- 10 illustrated in Figure 4.

- Appropriate proportions of Solution 1: PCR buffer, nucleoside triphosphates and DNA template in optional Reagent Vessel I (1) and Solution 2: Taq polymerase in optional Reagent Vessel II (2) are preferably first combined using two pumps, Pump I (3) and Pump II (4) and an optional mixing chamber (5) for gradient formation in HPLC. In some
- 15 embodiments, the mixed solutions are injection into the reaction tubing (6) by way of a single pump (not shown) which may be provided for example after a mixing chamber or, as shown here, optionally using two pumps (3, 4) where the DNA template is amplified in a reactor comprising four thermoregulated circulating water baths (7, 8, 9 and 10). The tubing (6) enters and exits all the four baths (7, 8, 9 and 10) one after another in series
- 20 which is referred to herein as a cycle. The temperature in the first bath (7) is preferably 95° C. The temperature in the second bath (8), which is referred to as the Cooling Bath I, is preferably 90° C. The temperature in the third bath (9), which is referred to as the Annealing Bath, is preferably 55° C. The temperature in the fourth bath (10) is preferably 72° C. The reaction mixture repeats the cycle for appropriate number of times (typically
- 25 30) which is specified in the optimization procedure. The cycle is repeated by the tubing (6) re-entering the bath (7) after emerging from bath (10) then continuing through bath (8), then bath (9), then (10) again and, to repeat back through the temperature chambers again (7, 8, 9 and 10).

- The tubing can be made from any material compatible with PCR or its inner
- 30 surface can be coated with such material. The preferred material is stainless steel or plastic used for medical purposes. The inner diameter of the tubing is between 3 mm and 20 mm,

- but can also be wider. In some cases when tubing with inner diameter over 4 mm is used a rigid spiral is inserted in the tubing to provide automatic mixing of solutions inside the tubing. Optional Pump III (11) is used for injecting additional quantities of the reagents (NTPs, Taq polymerase) from optional Reagent Vessel III (12) into the main tubing. After
- 5 the reaction mixture has circulated through the last bath in the last cycle, it optionally moves through Cooling Bath II (12) and further into the tank for storage of the PCR product, the Collection Vessel (13). The temperature in the Cooling Bath II (12) and Collection Vessel (13) is preferably 0° C.

- The machine is capable of performing PCR in 50-1000 liter of the reaction volume
- 10 per day. The apparatus provides for continuous flow of reaction mixture through the various baths. Depending upon the flow speed and length of tube within a given temperature bath, the length of time the reaction mixture will spend at a temperature during a cycle can be determined. The reaction times for each temperature is thus a function of the flow rate and the length of tube within a temperature bath. Various
- 15 configurations may be employed to achieve the desired lengths within the various temperature baths.

09753602.010301